Evidence map›Paper›PMID 37583821›Full record

ArticleACS medicinal chemistry letters2023

Synthesis and Evaluation of Bithiazole Derivatives As Potential α-Sarcoglycan Correctors.

Giovanni Ribaudo, Marcello Carotti, Alberto Ongaro, Erika Oselladore, Martina Scano, Giuseppe Zagotto, Dorianna Sandonà, Alessandra Gianoncelli

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Giovanni RibaudoDepartment of Molecular and Translational Medicine, University of Brescia, viale Europa 11, 25121 Brescia, Italy.ORCID https://orcid.org/0000-0003-3679-5530
Marcello CarottiDepartment of Biomedical Sciences, University of Padova, via Ugo Bassi 58/B, 35131 Padova, Italy.
Alberto OngaroDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.
Erika OselladoreDepartment of Molecular and Translational Medicine, University of Brescia, viale Europa 11, 25121 Brescia, Italy.ORCID https://orcid.org/0000-0002-2546-1343
Martina ScanoDepartment of Biomedical Sciences, University of Padova, via Ugo Bassi 58/B, 35131 Padova, Italy.
Giuseppe ZagottoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, via Marzolo 5, 35131 Padova, Italy.ORCID https://orcid.org/0000-0001-7053-4196
Dorianna SandonàDepartment of Biomedical Sciences, University of Padova, via Ugo Bassi 58/B, 35131 Padova, Italy.
Alessandra GianoncelliDepartment of Molecular and Translational Medicine, University of Brescia, viale Europa 11, 25121 Brescia, Italy.ORCID https://orcid.org/0000-0002-0816-5163

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

4'-Methyl-4,5'-bithiazoles were previously identified as cystic fibrosis transmembrane regulator (CFTR) correctors, thus being able to correct folding defective mutants of the channel regulating chloride transport through the membrane. Additionally, bithiazole derivative

Identifiers

PMID37583821
PMCPMC10424318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.